EGFR C797S: the single mutation that switches off osimertinib

Osimertinib was designed to solve a problem that killed the first two generations of EGFR inhibitors: the T790M gatekeeper mutation. It solved it by forming a covalent bond to a specific cysteine, C797, at the lip of the ATP pocket. That covalent anchor is also its Achilles heel. Mutate that one cysteine to a serine, C797S, and the bond can no longer form. The drug still drifts into the pocket, but it never latches, and the kinase keeps signaling. One amino acid, one lost bond, and a front-line lung cancer drug stops working.

How EGFR resistance escalated

EGFR-mutant non-small-cell lung cancer is a moving target. First- generation inhibitors like gefitinib and erlotinib work until the tumor acquires T790M, a threonine-to-methionine change at the gatekeeper position that adds bulk and restores the kinase's affinity for ATP. Osimertinib, a third-generation inhibitor, was built specifically to hit T790M-positive disease and became standard of care, including first-line (the FLAURA trial). The tumor's next move is C797S, which now appears as a leading on-target mechanism of acquired resistance to osimertinib.

Why C797S breaks the drug and T790M does not

The two mutations fail the drug for opposite reasons. T790M is a steric and affinity problem: the bigger methionine side chain changes the pocket and boosts ATP binding, so reversible drugs are outcompeted. Osimertinib gets around that by not relying on reversible affinity alone; it reacts with C797 to form a covalent bond, which makes its residence in the pocket effectively permanent. C797S attacks that solution directly. Serine cannot do the chemistry cysteine does, so the covalent bond simply never forms. The drug reverts to a weak reversible binder against a kinase that is still perfectly active.

Cis versus trans: the detail that decides treatment

When C797S and T790M coexist, their arrangement on the chromosome matters clinically. If the two mutations are in trans (on different alleles), a combination of a first-generation and a third-generation inhibitor can still suppress the kinase, because each allele is vulnerable to one of the two drugs. If they are in cis (on the same allele), no currently approved single EGFR inhibitor reliably binds, and the standard tyrosine-kinase- inhibitor strategies tend to fail. The same triple mutant is a driving reason new fourth-generation and allosteric EGFR inhibitors are being developed.

What this looks like in a docking run

Covalent chemistry aside, the reversible recognition step is something docking can illustrate. Dock osimertinib into wild-type EGFR and into a C797S model of the same pocket, and compare the predicted binding modes and score. The point is not to reproduce the covalent bond; it is to see that once the anchoring cysteine is gone, the reversible pose the drug is left with is weaker and less specific. Reading wild-type against mutant side by side is exactly the triage question a chemist faces: is my compound still engaging the pocket after this mutation, or has the mutation removed the interaction the whole molecule was built around?

Try it on the mutation

Open Studio and dock an EGFR inhibitor against wild-type and a mutant pocket in the same run. Liganx is mutation-aware molecular docking online: free and browser-based, so you can compare wild-type versus mutant binding and rank the shift before you commit a compound to synthesis or assay. It is a fast first pass on "does this mutation break my inhibitor," not a covalent-mechanism verdict.

Primary sources

• Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer (FLAURA). N Engl J Med 378, 113-125 (2018). doi:10.1056/NEJMoa1713137
• Leonetti A, Sharma S, Minari R, et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer 121, 725-737 (2019). doi:10.1038/s41416-019-0573-8